Curaleaf Rebuts Aurora After ASC Ruling on Aurora's ATM Program
CURLF sits 55% above its 52-week low of $5.4 on light trading volume (0.2× avg).
Summary
Curaleaf responded to an Alberta Securities Commission ruling on Aurora's ATM program, noting Aurora confirmed it halted ATM sales on August 18, 2026, and again pressed its US$5.00 per share hostile bid as an 86% premium ahead of the December 4, 2026 tender deadline.
Key Events · M&A and Partnerships · CURLF
-
Curaleaf Responds to ASC Ruling
On October 27, 2026, Curaleaf issued a statement responding to the Alberta Securities Commission's ruling regarding Aurora Cannabis's at-the-market program, arguing the ruling does not change the fundamental debate over its hostile bid.
-
Aurora ATM Sales Halted
Curaleaf said Aurora confirmed it stopped using its ATM program on August 18, 2026, shortly after Curaleaf challenged the activity, and has not used it since, sparing Aurora shareholders further dilution.
-
Offer Framed as 86% Premium
Curaleaf's enhanced offer implies approximately US$5.00 per share, an 86% premium to Aurora's unaffected volume-weighted average price of approximately US$2.75; Aurora had issued ATM shares as low as US$2.56, a 49% discount to the enhanced offer.
-
Diligence Access Still Blocked
Curaleaf says Aurora continues to exclude it from customary diligence while providing access to other parties, and that a process excluding Curaleaf cannot credibly be called a review of all strategic alternatives.
Analysis · CURLF · Life Sciences
With the December 4, 2026 tender deadline approaching, Curaleaf is keeping pressure on Aurora shareholders. The ASC ruling itself did not change the debate, but Curaleaf extracted a concrete concession: Aurora confirmed it stopped selling shares through its ATM on August 18, 2026 and has not used it since, removing a source of dilution that Curaleaf had challenged. Curaleaf also reframes its US$5.00 per share enhanced offer as an 86% premium to Aurora's unaffected volume-weighted average price of about US$2.75, countering Aurora's claim that the bid is a discount. The core issue remains Aurora's refusal to grant Curaleaf customary diligence while giving other parties access, which is the main obstacle to a deal that would combine into a company with more than US$1.5 billion of LTM revenue and at least US$40 million of expected annual cost synergies.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $8.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.